scispace - formally typeset
C

Chellan Kumarasamy

Researcher at University of Adelaide

Publications -  60
Citations -  536

Chellan Kumarasamy is an academic researcher from University of Adelaide. The author has contributed to research in topics: Meta-analysis & Cancer. The author has an hindex of 12, co-authored 51 publications receiving 381 citations. Previous affiliations of Chellan Kumarasamy include Charles Darwin University & SRM University.

Papers
More filters
Journal ArticleDOI

Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer-A protocol for systematic review and meta-analysis.

TL;DR: This meta-analysis protocol examines the comparative utility of neutrophil-lymphocyte-ratio, platelet-ly mphocyte- ratio, and monocyte-lyymphocyte-Ratio as a simple, inexpensive, and effective method for cancer prognosis, in multiple cancers.
Journal ArticleDOI

Prognostic Value of miRNAs in Head and Neck Cancers: A Comprehensive Systematic and Meta-Analysis

TL;DR: Results indicate that miRNAs have potential clinical value as prognostic biomarkers in HNC, with miR-21, 125b, 34c-5p and 18a, in particular, showing great potential as progostic molecular markers.
Journal ArticleDOI

Systematic review and meta-analysis of prognostic microRNA biomarkers for survival outcome in nasopharyngeal carcinoma.

TL;DR: It is noted that the combined effect estimate of HR across multiple studies indicated that increased miRNA expression in NPC potentially leads to poor overall survival, but further large-scale prospective studies on the clinical significance of the miRNAs, with sizable cohorts are necessary in order to obtain conclusive results.
Journal ArticleDOI

MiRNA predictors of pancreatic cancer chemotherapeutic response: A systematic review and meta-analysis

TL;DR: The results highlight multiple miRNAs that have possible associations with modulation of chemotherapy response in pancreatic cancer patients and further studies are needed to discover the molecular mechanisms underlying these associations before they can be suggested for use as biomarkers of response to chemotherapeutic interventions in Pancic cancer.